Citicoline and COVID-19-Related Cognitive and Other Neurologic Complications.
Yuda TuranaMichael NathanielRobert ShenSoegianto AliRajender R AparasuPublished in: Brain sciences (2021)
With growing concerns about COVID-19's hyperinflammatory condition and its potentially damaging impact on the neurovascular system, there is a need to consider potential treatment options for managing short- and long-term effects on neurological complications, especially cognitive function. While maintaining adequate structure and function of phospholipid in brain cells, citicoline, identical to the natural metabolite phospholipid phosphatidylcholine precursor, can contribute to a variety of neurological diseases and hypothetically toward post-COVID-19 cognitive effects. In this review, we comprehensively describe in detail the potential citicoline mechanisms as adjunctive therapy and prevention of COVID-19-related cognitive decline and other neurologic complications through citicoline properties of anti-inflammation, anti-viral, neuroprotection, neurorestorative, and acetylcholine neurotransmitter synthesis, and provide a recommendation for future clinical trials.
Keyphrases
- sars cov
- coronavirus disease
- cognitive decline
- clinical trial
- mild cognitive impairment
- risk factors
- cerebral ischemia
- induced apoptosis
- oxidative stress
- stem cells
- randomized controlled trial
- white matter
- fatty acid
- multiple sclerosis
- current status
- bone marrow
- open label
- endoplasmic reticulum stress
- smoking cessation
- replacement therapy
- phase iii